vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and AMPCO PITTSBURGH CORP (AP). Click either name above to swap in a different company.
ADMA BIOLOGICS, INC. is the larger business by last-quarter revenue ($139.2M vs $104.4M, roughly 1.3× AMPCO PITTSBURGH CORP). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs -55.2%, a 90.7% gap on every dollar of revenue. On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs 11.5%). ADMA BIOLOGICS, INC. produced more free cash flow last quarter ($34.6M vs $-64.0K). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs -2.6%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
Ampco-Pittsburgh Corporation is a specialty steel manufacturer headquartered in Downtown Pittsburgh, Pennsylvania. It is one of several companies to bear the Ampco name, and it should not be confused with the Milwaukee-based copper base alloy producer, Ampco Metal Inc.; the Miami-based cabinetry company; the Swiss aluminum corporation; or the Dallas-based tool company. Ampco was formed in 1929 and is a conglomerate made up of several previously established small steel makers. Five small compa...
ADMA vs AP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $104.4M |
| Net Profit | $49.4M | $-57.7M |
| Gross Margin | 63.8% | — |
| Operating Margin | 45.1% | -54.0% |
| Net Margin | 35.5% | -55.2% |
| Revenue YoY | 18.4% | 11.5% |
| Net Profit YoY | -55.9% | -1958.9% |
| EPS (diluted) | $0.20 | $-2.87 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $104.4M | ||
| Q3 25 | $134.2M | $103.7M | ||
| Q2 25 | $122.0M | $108.9M | ||
| Q1 25 | $114.8M | $99.2M | ||
| Q4 24 | $117.5M | $93.6M | ||
| Q3 24 | $119.8M | $92.1M | ||
| Q2 24 | $107.2M | $107.1M | ||
| Q1 24 | $81.9M | $110.0M |
| Q4 25 | $49.4M | $-57.7M | ||
| Q3 25 | $36.4M | $-2.2M | ||
| Q2 25 | $34.2M | $-7.3M | ||
| Q1 25 | $26.9M | $1.1M | ||
| Q4 24 | $111.9M | $3.1M | ||
| Q3 24 | $35.9M | $-2.0M | ||
| Q2 24 | $32.1M | $2.0M | ||
| Q1 24 | $17.8M | $-2.7M |
| Q4 25 | 63.8% | — | ||
| Q3 25 | 56.3% | — | ||
| Q2 25 | 55.1% | — | ||
| Q1 25 | 53.2% | — | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 49.8% | — | ||
| Q2 24 | 53.6% | — | ||
| Q1 24 | 47.8% | — |
| Q4 25 | 45.1% | -54.0% | ||
| Q3 25 | 38.0% | 1.1% | ||
| Q2 25 | 35.1% | -2.8% | ||
| Q1 25 | 30.4% | 3.9% | ||
| Q4 24 | 32.6% | 5.5% | ||
| Q3 24 | 33.1% | 2.0% | ||
| Q2 24 | 36.6% | 4.7% | ||
| Q1 24 | 26.7% | 0.1% |
| Q4 25 | 35.5% | -55.2% | ||
| Q3 25 | 27.1% | -2.1% | ||
| Q2 25 | 28.1% | -6.7% | ||
| Q1 25 | 23.4% | 1.2% | ||
| Q4 24 | 95.2% | 3.3% | ||
| Q3 24 | 30.0% | -2.1% | ||
| Q2 24 | 29.9% | 1.9% | ||
| Q1 24 | 21.7% | -2.5% |
| Q4 25 | $0.20 | $-2.87 | ||
| Q3 25 | $0.15 | $-0.11 | ||
| Q2 25 | $0.14 | $-0.36 | ||
| Q1 25 | $0.11 | $0.06 | ||
| Q4 24 | $0.45 | $0.16 | ||
| Q3 24 | $0.15 | $-0.10 | ||
| Q2 24 | $0.13 | $0.10 | ||
| Q1 24 | $0.08 | $-0.14 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $10.7M |
| Total DebtLower is stronger | $72.1M | $117.9M |
| Stockholders' EquityBook value | $477.3M | $32.6M |
| Total Assets | $624.2M | $495.4M |
| Debt / EquityLower = less leverage | 0.15× | 3.61× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | $10.7M | ||
| Q3 25 | $61.4M | $15.0M | ||
| Q2 25 | $90.3M | $9.9M | ||
| Q1 25 | $71.6M | $7.1M | ||
| Q4 24 | $103.1M | $15.4M | ||
| Q3 24 | $86.7M | $11.8M | ||
| Q2 24 | $88.2M | $7.9M | ||
| Q1 24 | $45.3M | $10.8M |
| Q4 25 | $72.1M | $117.9M | ||
| Q3 25 | $72.4M | $119.0M | ||
| Q2 25 | — | $115.9M | ||
| Q1 25 | — | $115.0M | ||
| Q4 24 | $72.3M | $116.4M | ||
| Q3 24 | — | $116.0M | ||
| Q2 24 | — | $119.4M | ||
| Q1 24 | — | $116.2M |
| Q4 25 | $477.3M | $32.6M | ||
| Q3 25 | $431.2M | $60.1M | ||
| Q2 25 | $398.3M | $62.7M | ||
| Q1 25 | $373.4M | $64.6M | ||
| Q4 24 | $349.0M | $58.9M | ||
| Q3 24 | $231.9M | $61.3M | ||
| Q2 24 | $188.3M | $58.0M | ||
| Q1 24 | $153.7M | $56.3M |
| Q4 25 | $624.2M | $495.4M | ||
| Q3 25 | $568.7M | $524.4M | ||
| Q2 25 | $558.4M | $537.2M | ||
| Q1 25 | $510.6M | $536.2M | ||
| Q4 24 | $488.7M | $530.9M | ||
| Q3 24 | $390.6M | $547.4M | ||
| Q2 24 | $376.4M | $560.8M | ||
| Q1 24 | $350.9M | $565.8M |
| Q4 25 | 0.15× | 3.61× | ||
| Q3 25 | 0.17× | 1.98× | ||
| Q2 25 | — | 1.85× | ||
| Q1 25 | — | 1.78× | ||
| Q4 24 | 0.21× | 1.98× | ||
| Q3 24 | — | 1.89× | ||
| Q2 24 | — | 2.06× | ||
| Q1 24 | — | 2.06× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $2.7M |
| Free Cash FlowOCF − Capex | $34.6M | $-64.0K |
| FCF MarginFCF / Revenue | 24.8% | -0.1% |
| Capex IntensityCapex / Revenue | 0.8% | 2.7% |
| Cash ConversionOCF / Net Profit | 0.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | $-8.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $2.7M | ||
| Q3 25 | $13.3M | $6.3M | ||
| Q2 25 | $21.1M | $-2.3M | ||
| Q1 25 | $-19.7M | $-5.3M | ||
| Q4 24 | $50.2M | $7.5M | ||
| Q3 24 | $25.0M | $11.4M | ||
| Q2 24 | $45.6M | $-5.3M | ||
| Q1 24 | $-2.2M | $4.5M |
| Q4 25 | $34.6M | $-64.0K | ||
| Q3 25 | $-1.1M | $3.3M | ||
| Q2 25 | $18.7M | $-3.8M | ||
| Q1 25 | $-24.4M | $-7.5M | ||
| Q4 24 | $47.5M | $3.7M | ||
| Q3 24 | $24.0M | $8.4M | ||
| Q2 24 | $43.6M | $-8.0M | ||
| Q1 24 | $-4.6M | $1.7M |
| Q4 25 | 24.8% | -0.1% | ||
| Q3 25 | -0.8% | 3.2% | ||
| Q2 25 | 15.3% | -3.5% | ||
| Q1 25 | -21.2% | -7.5% | ||
| Q4 24 | 40.4% | 4.0% | ||
| Q3 24 | 20.0% | 9.1% | ||
| Q2 24 | 40.7% | -7.5% | ||
| Q1 24 | -5.6% | 1.5% |
| Q4 25 | 0.8% | 2.7% | ||
| Q3 25 | 10.7% | 2.9% | ||
| Q2 25 | 2.0% | 1.3% | ||
| Q1 25 | 4.1% | 2.2% | ||
| Q4 24 | 2.3% | 4.0% | ||
| Q3 24 | 0.9% | 3.2% | ||
| Q2 24 | 1.9% | 2.5% | ||
| Q1 24 | 2.9% | 2.6% |
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.62× | — | ||
| Q1 25 | -0.73× | -4.62× | ||
| Q4 24 | 0.45× | 2.40× | ||
| Q3 24 | 0.70× | — | ||
| Q2 24 | 1.42× | -2.64× | ||
| Q1 24 | -0.12× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
AP
| Forged And Cast Mill Rolls | $67.0M | 64% |
| Air Handling Systems | $14.3M | 14% |
| Heat Exchange Coils | $13.1M | 13% |
| Centrifugal Pumps | $10.3M | 10% |
| Forged Engineered Products | $4.0M | 4% |
